Parallax Volatility Advisers’s United Therapeutics UTHR Stock Holding History

Parallax Volatility Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,000	Closed	-$7.06M	–	2165
2024 Q4	$7.06M	Buy	+20,000	New	+$7.35M	0.01%	692
2024 Q3	–	Sell	-20,000	Closed	-$6.37M	–	2272
2024 Q2	$6.37M	Buy	+20,000	New	+$5.29M	0.01%	629
2023 Q1	–	Sell	-20,200	Closed	-$5.62M	–	3218
2022 Q4	$5.62M	Sell	20,200 -105,100	-84%	-$26.5M	0.01%	981
2022 Q3	$26.2M	Buy	+125,300	New	+$28M	0.04%	448
2019 Q3	–	Sell	-64,800	Closed	-$5.06M	–	3519
2019 Q2	$5.06M	Buy	+64,800	New	+$6.06M	0.01%	728
2019 Q1	–	Sell	-2,200	Closed	-$240K	–	4079
2018 Q4	$240K	Sell	2,200 -40,000	-95%	-$4.64M	﹤0.01%	1704
2018 Q3	$5.4M	Buy	+42,200	New	+$5.22M	0.01%	686
2016 Q1	–	Sell	-25,000	Closed	-$3.92M	–	3727
2015 Q4	$3.92M	Buy	+25,000	New	+$3.64M	0.01%	772
2015 Q3	–	Sell	-19,400	Closed	-$3.38M	–	4217
2015 Q2	$3.38M	Buy	+19,400	New	+$3.49M	0.01%	867

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Parallax Volatility Advisers's UTHR Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 3,344 shares — an estimated $1.18M sold.

Parallax Volatility Advisers first reported a position in UTHR in Q2 2017 and held it in 10 quarters. The position peaked at $5.7M in Q2 2017. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

Parallax Volatility Advisers reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 3,344 United Therapeutics shares in Q1 2025, an estimated $1.18M.
Parallax Volatility Advisers first reported a position in United Therapeutics in Q2 2017 and held it in 10 quarters.
Parallax Volatility Advisers's United Therapeutics position peaked at $5.7M in Q2 2017.
671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.